

AI-Enhanced Treatment Planning & Quality Assurance
Technical Approach
PrecisionRad leverages deep learning AI to accelerate and refine treatment blueprints. This includes AI-assisted contouring of tumors and organs at risk (OARs) on CT/MRI scans, intelligent algorithms that propose optimal radiation beam arrangements and fluence maps, and predictive dosimetry models. Automated systems flag plans for quality assurance, ensuring adherence to best practices, while genomic insights directly inform the definition of biological target volumes, especially for radioresistant sub-regions.

Scientific Impact
This AI integration drives more consistent and highly accurate target delineation, reducing inter-observer variability. It opens avenues for exploring novel, biologically-informed planning strategies where, for instance, radioresistant tumor regions identified via genomics are specifically targeted. This capability is foundational for developing sophisticated, biologically adaptive radiotherapy approaches.

Business Value
- Increase Efficiency: Streamline the complex treatment planning process.

- Improve Quality: Enhance treatment plan consistency and quality for better patient outcomes.

- Standardize Best Practices: Promote uniform, high-quality care across the institution.

- Enable Innovation: Establish a clear pathway to advanced, adaptive, and personalized radiotherapy.

- Enhance Reputation: Position the clinic as an innovative leader in oncology.


Genomic Use Cases Integration
PrecisionRad utilizes its analyze_single_variant AI capability to directly enhance treatment planning and QA by:

Informing target definition: If specific tumor sub-regions are identified (e.g., through multi-sample analysis or imaging-genomic correlation) to harbor mutations predicted by the AI to confer high radioresistance (e.g., specific TP53 gain-of-function variants with strong pathogenic scores), these regions can be delineated as biological targets for dose escalation (dose painting).
Guiding selection of OAR constraints: Germline variants analyzed by analyze_single_variant that indicate heightened sensitivity of certain normal tissues to radiation can inform more conservative dose constraints for those specific OARs during planning.
Contributing to QA by providing biological rationale: When AI-driven plans incorporate dose escalation to genomically-defined resistant areas, the underlying analyze_single_variant predictions (pathogenicity, delta_score) provide a verifiable biological basis for these advanced planning decisions, enhancing the QA process.

Radio-Genomics & Biomarker Integration for Personalization
Technical Approach
Our platform seamlessly integrates multi-modal patient data. This includes genomic information (germline/somatic variants analyzed via an Evo2-style analyze_single_variant API for functional impact scores), transcriptomics, and proteomics, alongside quantitative features extracted from CT, PET, and MRI scans via advanced radiomics pipelines. Sophisticated AI models then correlate these comprehensive molecular and imaging biomarkers with radiation response and toxicity profiles.

Scientific Impact
This holistic approach provides a much deeper understanding of the biological underpinnings of tumor radiosensitivity and resistance, as well as individual predispositions to normal tissue toxicity. It enables non-invasive tumor characterization through radiomics and helps identify which patients are most likely to benefit from personalized strategies like dose escalation/de-escalation, specific radiosensitizers, or alternative therapeutic combinations based on their unique genomic and imaging profile.

Business Value
- Accelerate Research: Stratify patients more effectively for clinical trials and biomarker development.

- Attract Patients: Draw in patients seeking advanced, personalized treatment options.

- Support Value-Based Care: Optimize treatment selection and resource allocation for better outcomes and cost-effectiveness.


Genomic Use Cases Integration
PrecisionRad's integrated AI-powered analyze_single_variant capability is fundamental to personalizing radiation therapy. It facilitates:

Prediction of tumor radiosensitivity or resistance based on functional impacts of somatic mutations in DNA repair/cell cycle genes.
Forecasting of normal tissue radiotoxicity by analyzing germline variants influencing radiation susceptibility.
Enablement of biologically guided dose painting by identifying radioresistant tumor sub-regions via their mutational profiles.
Rapid interpretation of VUS in hereditary cancer genes for holistic patient context in radiotherapy and genetic counseling.
Guidance on concurrent/adjuvant systemic therapies by assessing how tumor mutations affect sensitivity to those agents.
Improved patient stratification for clinical trials and discovery of novel radio-genomic biomarkers.
This tailors radiation plans by understanding individual tumor/patient genomics to maximize efficacy and minimize side effects.


Intelligent Adaptive Radiotherapy (ART) Support
Technical Approach
PrecisionRad's ART module employs AI for automated detection of anatomical and biological changes using daily/weekly on-board imaging (e.g., CBCT). It performs rapid simulations of the dosimetric impact of these changes on the current treatment plan. AI-driven algorithms then provide recommendations for replanning triggers, potentially further refined by genomic biomarkers that predict a tumor's propensity for rapid evolution or resistance development during therapy.

Scientific Impact
This capability ensures more accurate and adaptive radiation dose delivery throughout the entire treatment course, responding dynamically to tumor shrinkage, swelling, or shifts in organs at risk. It enables robust research into optimal ART strategies, allowing for stratification of patients based on genomic predictors to identify who would benefit most from adaptation, thereby personalizing the adaptive approach itself.

Business Value
- Lead in Advanced Care: Become a leader in responsive, adaptive cancer treatment.

- Improve Patient Outcomes: Proactively manage treatment to enhance efficacy and reduce complications.

- Gain Competitive Advantage: Offer superior, dynamic treatment management.


Genomic Use Cases Integration
PrecisionRad's analyze_single_variant AI can inform ART strategies by:

Identifying tumors with genomic signatures (e.g., mutations in genes associated with rapid clonal evolution or acquired resistance, as flagged by the AI) that may benefit most from frequent monitoring and adaptive replanning.
During adaptation, if new imaging or biopsy data reveals emerging resistant subclones with specific mutations, the AI's functional impact assessment of these new variants can guide adjustments in the adapted plan.
Providing a biological basis for the frequency and nature of adaptations, moving beyond purely geometric changes to incorporate predictive genomics into the ART decision loop.

Treatment Outcome & Toxicity Prediction
Technical Approach
PrecisionRad develops advanced predictive models for Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP). These models uniquely incorporate not only clinical, dosimetric, and imaging data, but also crucially, detailed genomic risk factors derived from our analyze_single_variant AI's analysis (e.g., summed impact scores of relevant mutations). An LLM then facilitates the presentation of these personalized risk/benefit profiles in an accessible manner.

Scientific Impact
This integrated approach leads to more accurate and personalized prognostication for patients. It allows for better-informed shared decision-making conversations by clearly outlining individualized predictions. Furthermore, it helps identify complex interacting factors, including specific genomic signatures and their AI-predicted functional consequences, that drive treatment success or failure, offering rich avenues for translational research.

Business Value
- Enhance Patient Counseling: Improve communication and manage expectations with personalized predictions.

- Drive Quality Improvement: Use data for internal benchmarking and developing better survivorship plans.

- Demonstrate Innovation: Showcase a commitment to data-driven, patient-centered care.


Genomic Use Cases Integration
The analyze_single_variant genomic engine is crucial for enhancing TCP/NTCP models within PrecisionRad by:

For TCP, providing AI-derived functional impact scores (pathogenicity, delta_score) of somatic tumor mutations, quantifying their likely contribution to radioresistance (e.g., a pathogenic TP53 variant flagged by the AI) or sensitivity, directly refining outcome predictions.
For NTCP, assessing germline variants analyzed by analyze_single_variant in pathways like DNA repair and inflammation to identify individual patient predispositions to specific radiation toxicities.
These granular genomic risk factors, derived from analyze_single_variant's outputs, allow for the creation of more accurate and personalized predictions of treatment success and potential side effects, improving shared decision-making.

Knowledge Integration & Research Support
Technical Approach
The platform features an LLM for intuitive, natural language querying of extensive knowledge bases, including radiation oncology guidelines, the latest published research, and crucially, internal anonymized patient cohort data enriched with genomic findings from our analyze_single_variant AI. It also includes robust tools for structured data capture optimized for research, and intelligent clinical trial matching algorithms that leverage comprehensive patient profiles including detailed genomic markers.

Scientific Impact
This capability actively facilitates evidence-based practice and fosters a culture of continuous learning within the clinical team. It streamlines the collection of high-quality, multi-modal data, essential for sophisticated clinical and translational research. By incorporating deep genomic insights from the AI into trial matching, it significantly improves accrual to highly relevant, genomically-informed clinical trials, advancing the science of personalized radiation oncology.

Business Value
- Boost Research Profile: Elevate the institution's contribution to oncological knowledge.

- Drive Innovation: Support continuous quality improvement and innovation in patient care.

- Attract Talent & Funding: Become a magnet for top talent and research funding through a commitment to data-driven practice.


Genomic Use Cases Integration
PrecisionRad's analyze_single_variant capability fuels knowledge integration and research by:

Generating standardized, AI-interpreted functional impact data (predictions, delta scores, confidence) for every analyzed variant, creating rich, queryable genomic datasets essential for retrospective and prospective research.
Enabling researchers to investigate correlations between specific AI-predicted variant effects (e.g., 'Likely Pathogenic' with high negative delta_score) and clinical outcomes, thereby accelerating the discovery and validation of novel radio-genomic biomarkers.
Facilitating more precise patient stratification for clinical trials by incorporating the AI's assessment of variant pathogenicity and functional impact, moving beyond simple gene lists to actual predicted biological consequences for trial eligibility and arm assignment.
